Dr. Reddy's Laboratories Share Price

Dr. Reddy's Laboratories is a worldwide pharmaceutical corporation headquartered in Hyderabad, Telangana, India. Kallam Anji Reddy, who had worked at the mentor institute Indian Drugs and Pharmaceuticals Limited, started the company. A vast variety of pharmaceuticals are produced and sold by Dr. Reddy in India and other countries. They produce about 190 medications, and 60 active pharmaceutical ingredients (APIs) for the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology products, among other things.

“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”

- DR. K ANJI REDDY

With one medicine in a 60-tonne facility close to Hyderabad, Dr. Reddy's launched its business in the Active Pharmaceutical Ingredients (API) category in 1984. It sent its first shipment of Methyldopa medication to West Germany in 1986. It is one of the top three API providers worldwide. They also entered the international market this year with the introduction of the API Methyldopa. In 1987, they received their first USFDA approval for the API Ibuprofen. They have been manufacturing omeprazole, one of the most well-known products, since 1991. They entered Russia, which at the time was the biggest international market, in 1992. To direct research into new cancer and diabetes medicines, the Dr. Reddy's Research Foundation was founded in 1993.

To address the needs of children, teenagers, and women who are at risk in both the economic and social spheres,In 1996, Dr. Reddy's Foundation was founded. They began their biologics business in 1998 with the goal of providing inexpensive access to expensive pharmaceuticals to Indian patients.

As part of their continued global expansion, they bought BMS Laboratories Limited and Meridian Healthcare in the UK in 2002 and released a drug for advanced prostate cancer in India, becoming the first company to introduce Bicalutamide in India. The corporation established Dr. Reddy's Foundation for Health Education and a breast cancer helpline in Mumbai.

In the US, ibuprofen was first made accessible as a generic medication in 2003.

To treat autoimmune diseases and tumors, including non-lymphoma, Hodgkin's introduced the first monoclonal antibody biosimilar in history in 2007. In 2009, revenue in Russia and the CIS exceeded $150 million. In 2012, revenue exceeded USD 2 billion.

By 2016 the business entered the market for branded consumer health goods by purchasing six OTC brands from Ducere Pharma The company just announced its entry into Colombia with a variety of excellent, cost-effective medications for cancer patients.

By purchasing six over-the-counter (OTC) brands from Ducere Pharma in 2016, the company entered the market for branded consumer health products. The business announced its arrival in Colombia with a selection of top-notch, reasonably priced drugs for people with cancer.

In 2017 they expanded their commercial operations in Europe as they introduced the generics portfolio in France. The company's subsidiary Aurigene Discovery Technologies launched a particular initiative to create oral immuno-oncology drugs in 2018. A crucial generic medicine for the treatment of opioid addiction was successfully introduced in the US. 2019 saw the entry of Dr. Reddy's Nutrition into the Indian nutrition market with the launch of Celevida, a ground-breaking product. For the cosmetic and aesthetic area, GLOWRIA, a 40-person, all-female medical representation team, was created. To provide a wide variety of COVID-19 medicines to India as the coronavirus pandemic spread around the globe, they got into significant relationships with international innovation businesses. In the US, they introduced the first generic Otic suspension product. In addition to some anti-allergy brands from the Glenmark portfolio in Russia, Ukraine, Kazakhstan, and Uzbekistan, they bought specific business divisions of Wockhardt in India. They joined the Science Based Targets program as the first pharmaceutical business in India.

Corporate Social Responsibility Information

The Company may carry out the following CSR-related projects or programs:

• Fighting against hunger, poverty, and malnutrition, encouraging preventative care, cleanliness, and the provision of safe drinking water.
• Projects to improve livelihoods and promote education, including special education and employment-enhancing vocation skills, particularly among children, women, older people, and people with disabilities.
• Maintaining the quality of soil, air, and water while ensuring environmental sustainability, ecological balance, animal welfare, protection of flora and fauna, and agroforestry.
• Education to promote Olympic, paralympic, and rural sports that are recognized nationwide.
• Contribution to the prime minister's national relief fund, the PM CARES Fund, or any other fund established by the central government for the socio-economic development, relief, and welfare of the scheduled caste, tribes, other underprivileged classes, minorities, and women
• Contributions to public-funded universities in the field of technology, national laboratories, and autonomous bodies engaged in conducting research in the fields of atomic energy, science, and technology
• Contributions to incubators or research and development projects in the fields of science, technology, engineering, and medicine, funded by the Central Government or State Government or Public Sector Undertaking or any agency of the Central Government or State Government
• Contributions to publicly funded research universities, national laboratories, and autonomous organizations conducting research in the fields of atomic energy, science, technology, biotechnology, pharmaceuticals, electronics, and information, as well as defense, agricultural, scientific, and industrial research, engineering, and medicine and listed in Schedule VII of the Act and its implementing regulations
• projects for rural development.
• Construction in slum areas.
• Any other activities or subjects listed in Schedule VII of the Companies Act, 2013 (the Act) and the rules made thereunder, as amended from time to time, and circulars/notifications issued by statutory authorities.
• Disaster management, including relief, rehabilitation, and reconstruction activities.